Currently in clinical trials, applying monoclonal antibodies that bind to myostatin to inhibit its function is a potential therapy to treat cachexia syndrome in cancer patients (Nicole, Lisa, Wolfram, Anker, & Stephan, 2014). The gene discussed is MSTN; the disease is cancer.